Camptothecins are a very promising group of strong topoisomerase I poisons that have shown good activity against a variety of human cancers in clinical trials. Several key contributions to our understanding of the cytotoxic mechanisms of camptothecins have been made with studies of simian virus 40 (SV40), a small double strand DNA virus which makes such extensive use of host cell chromosomal proteins and enzymes of DNA replication and transcription that it is considered a """"""""minichromosome"""""""" and model for the mammalian replicon. As a model system, SV40 has unique advantages and has made many contributions to our understanding of mammalian DNA replication and transcription. The hypothesis of this proposed study is that our understanding of the molecular biology of camptothecin action can be significantly advanced by two developments of the SV40 model system: (1) the study of camptothecin-resistant mutants of CV-1 host cells for SV40 infections and (2) studies using mutants of SV40 with greatly increased infectivity for human cells. The primary goal of the studies is to understand the structure and processing of camptothecin-induced DNA lesions and how these can be modulated by other treatments. The unique advantages of the SV40 system will allow us to analyze disruptions in DNA replication and transcription in unusual molecular detail. Secondary goals include complete characterization of the camptothecin resistant CV-1 cell mutants, studies of camptothecin effects on DNA replication in human genetic instability syndromes hypersensitive to camptothecins and understanding of the roles of topoisomerases I and IIbeta in transcription. The rational for the studies is that improved understanding of camptothecin-induced damage and its processing will provide valuable information for the design of new drugs of this class and for new treatment combinations.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA080961-02
Application #
6377080
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Program Officer
Wolfe, Paul B
Project Start
2000-05-08
Project End
2003-04-30
Budget Start
2001-05-01
Budget End
2002-04-30
Support Year
2
Fiscal Year
2001
Total Cost
$198,450
Indirect Cost
Name
Ohio State University
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
098987217
City
Columbus
State
OH
Country
United States
Zip Code
43210
Gao, Hanlin; Yamasaki, Edith F; Chan, Kenneth K et al. (2003) DNA sequence specificity for topoisomerase II poisoning by the quinoxaline anticancer drugs XK469 and CQS. Mol Pharmacol 63:1382-8
Snapka, R M; Gao, H; Grabowski, D R et al. (2001) Cytotoxic mechanism of XK469: resistance of topoisomerase IIbeta knockout cells and inhibition of topoisomerase I. Biochem Biophys Res Commun 280:1155-60
Huang, K C; Gao, H; Yamasaki, E F et al. (2001) Topoisomerase II poisoning by ICRF-193. J Biol Chem 276:44488-94
Gao, H; Yamasaki, E F; Chan, K K et al. (2000) Chloroquinoxaline sulfonamide (NSC 339004) is a topoisomerase IIalpha/beta poison. Cancer Res 60:5937-40